3. Check uterine cavity for rupture or retained products of conception 4. Give rectal misoprostol. 5. Bimanual compression. In lesser bleeding, rub up contraction and consider putting baby to breast. 6. Tamponade uterine bleeding with uterine packing or balloon. 7. Surgical haemostasis e.g. brace suture, haemostatic square sutures, internal iliac ligation, and hysterectomy. 8. Consider calling an interventional radiologist for embolisation if still worrying bleeding after surgery has done all it can.
capacity to keep arterial pH above 7.0. a. Two big cannulae, blood warmers, pressure infusers. b. Monitor pulse, BP, S p O 2 , ABGs, urine output. 3. Use crystalloid for fluid resuscitation; consider O Negative blood whilst awaiting group-specific or cross-matched blood. 4. Give uterotonics as indicated (see below) 5. Maintain core temperature above 35°C. 6 . Prepare for theatre (reduced dose thiopental or use ketamine as induction agent). 7. Assess and treat coagulopathy. 8 . Give 1g tranexamic acid bolus, followed by infusion. 9. Liaise closely with Blood Bank and consultant haematologist. Definition: Blood loss exceeding 1500 ml and ongoing or more than 150 ml per minute.
Drugs for Postpartum Haemorrhage
Tachycardia, hypotension, and vasoconstriction in an obstetric patient represent severe hypovolaemia: A young pregnant woman will typically maintain her vital signs relatively normally until more than 2 litres are lost, but thereafter decompensation might be very quick. Coagulopathy may cause haemorrhage. Haemorrhage causes coagulopathy. In the emergency situation, err on the side of caution: if the blood loss -especially the cumulative blood loss -looks alarming, then activate the massive haemorrhage pathway.
Phase 1: If a woman in a labour ward room has bled > 1500ml, or if ongoing bleeding appears excessive to the attending midwife, pull the emergency knob (red triangle on the wall).
This should bring a senior obstetrician, a senior anaesthetist, the labour midwife ward coordinator. Please note, this will not include alerting the porter. If the woman is already in maternity theatre and begins to bleed excessively, proceed straight to Phase 2. On arrival, the senior obstetrician, or the most senior person present, should assess immediately if the massive haemorrhage protocol should be activated (Phase 2) 
The Sample Taker should:
Complete request forms, take blood samples, and label samples correctly and fully at the bedside, where possible BEFORE any blood components have been given. Samples to be taken: FBC, coagulation screen, fibrinogen (to be decided by senior obstetrician depending on the clinical picture), U&E's, Crossmatch The obstetrician to decide if Fibrinogen required -this is needed particularly in cases of placental abruption and cases of intra-uterine death and ongoing bleeding Give samples/forms to Runner to take to laboratory as quickly as possible. Ensure IV access is adequate. Document all actions, observations and fluids infused. Ensure that all blood used is autofated (ask midwife to do this) If O Neg emergency blood is used, complete documentation attached and return to blood bank after the emergency is over. Further samples (FBC, PT, aPTT, Fibrinogen, U&E's) should be taken every 60 mins while haemorrhage requires active management. Use of TEG (located in Cardiac ITU or Cardiac theatres) should be considered to direct blood product transfusion.
Team
Leader will lead and coordinate obstetric management of the haemorrhage (surgical and pharmacological), including discussion with an interventional radiologist if arterial embolisation is being considered.
3. The senior anaesthetist present will direct the resuscitation, and the fluid/blood product management. He/she will also consult the on-call consultant haematologist for advice on blood product use, and especially if recombinant factor VIIa is being considered.
Resuscitation Priorities
The priorities in resuscitation include in decreasing order of importance:
Restoring blood volume to maintain tissue perfusion and oxygenation.
Restoration of oxygen-carrying capacity with adequate haemoglobin concentration. Securing haemostasis through surgical treatment of the cause of bleeding or by correcting coagulopathy.
Delay in restoration of circulating volume (with warmed crystalloid fluids, then blood) may result in tissue hypoperfusion, organ failure and disseminated intravascular coagulopathy. activation of the coagulation system. In pregnancy this might result from major placental abruption, retained dead fetus, severe pre-eclampsia or amniotic fluid embolism. If you are in doubt, discuss it with a haematologist.
Complications of resuscitation

Intraoperative cell salvage in Obstetrics (ICSO)
See the separate procedure for ICSO. ICSO can be used in the management of obstetric haemorrhage. While it is usually indicated for anticipated haemorrhage and for anaemia, it can be set up in less than five minutes and is indicated in the emergency setting if bleeding continues and you expect there to be more to salvage and process. Always send for senior assistance if you are in this position -the patient is haemorrhaging. Check with the ODP and consider sending for another ODP.
In ongoing massive haemorrhage, do not use the reinfusion filter. The filter will slow reinfusion down so far that it cannot be used for reinfusion as part of intraoperative red cell therapy. In this case, the balance of risk, favours rapid return of salvaged red cells. Ensure volume infused is recorded.
Interventional Radiology
This can be considered for elective cases where a MOH is anticipated e.g.; placenta accreta Bilateral placement of catheters into the internal iliac arteries, with perioperative balloon occlusion or transcatheter arterial embolisation have been used effectively to control massive obstetric haemorrhage. However, it is a prolonged procedure needing careful planning and taking place in the radiology department. It is very unlikely to be effectively employed in an acute situation if catheters are not already in place.
Heparin and diclofenac
Diclofenac is an important component of postoperative pain relief, which itself promotes mobilisation -the mainstay of postoperative thromboprophylaxis. It does not usually need to be withheld as a precautionary measure. When the bleeding has resolved the anaesthetist and obstetrician should discuss its use. Refrain from using it if urine output is low. Please note: Diclofenac is contraindicated in patients with known bleeding disorders and women with severe PET &/or sepsis.
Low molecular weight heparin is the main pharmacological agent in postoperative thromboprophylaxis. It is unlikely to cause or exacerbate postpartum haemorrhage that has resolved. It does not usually need to be withheld as a precautionary measure. When the bleeding has resolved the anaesthetist and obstetrician should discuss its use.
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Women who refuse blood transfusion -communication and management plan See also Trust wide Policy for the Transfusion of patients who refuse consent to the use of blood and blood products. CLIN-POL-003-10.
Key points: Indicate risk in notes.
After full checking of the woman's view, and appropriate counselling, the appropriate patient disclaimer paperwork should be mutually completed between the woman and the consultant. This can be a consultant anaesthetist at the consultant anaesthetic clinic. Standard information leaflets on refusal of blood components should be given to patient and this action should be documented in notes.
There should be a management plan in the hand-held record, (with key points transcribed to the hospital notes). 
OPTIMISATION of patient's haemoglobin
DISSEMINATION AND IMPLEMENTATION
STAFF COMPLIANCE STATEMENT
Clinical Guidelines assist in decision making; they do not replace clinical judgement. Regardless of the strength of the strength of evidence, it remains the responsibility of the clinician to interpret the application of the clinical guidance to local circumstances and the needs and wishes of the individual patient. Where variations of any kind do occur, it is important to document the variations and the reason for them in the patient's health record.
EQUALITY & DIVERSITY STATEMENT
Throughout its activities, the Trust will seek to treat all people equally and fairly. This includes those seeking and using the services, employees and potential employees. No-one will receive less favourable treatment on the grounds of sex/gender (including Trans People), disability, marital status, race/colour/ethnicity/nationally, sexual orientation, age, social status, their trade union activities, religion/beliefs or caring responsibilities nor will they be disadvantaged by conditions or requirements which cannot be shown to be justifiable. All staff, whether part time, full-time, temporary, job share or volunteer; service users and partners will be treated fairly and with dignity and respect. 
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